文献速递浆细胞疾病

血清B细胞成熟抗原水平正常化可预测多发性骨髓瘤患者治疗后的总生存期

Normalization of serum B-cell maturation antigen levels predicts overall survival among multiple myeloma patients starting treatment.
PubMed 文献 · Br J Haematol · 2020-05-22

本研究探讨血清B细胞成熟抗原(sBCMA)正常化(<82·59 ng/ml)与多发性骨髓瘤(MM)患者生存及疗效的关系。开始新治疗时sBCMA即正常的患者无进展生存期(P=0·0398)和总生存期(P=0·0217)均更优;治疗中sBCMA降至正常的患者总生存期改善(P=0·0078),总缓解率亦显著提高(P<0·0001)。

要点

  • 开始治疗时sBCMA<82·59 ng/ml者PFS(P=0·0398)和OS(P=0·0217)更优。
  • 治疗中sBCMA降至正常范围者OS改善(P=0·0078)。
  • sBCMA正常化者总缓解率显著提高(P<0·0001)。

核心结论

  • sBCMA正常化可能是MM患者治疗期间OS的准确预测指标,并预示更高的缓解可能性。

研究设计与样本

  • 研究纳入开始新治疗的多发性骨髓瘤(MM)患者,分析sBCMA水平正常化与生存及疗效的关系。

主要发现

  • 开始治疗时sBCMA<82·59 ng/ml的患者较≥82·59 ng/ml者PFS更优(P=0·0398)、OS更优(P=0·0217)。
  • 开始治疗时sBCMA≥82·59 ng/ml的患者中,sBCMA降至正常范围者OS改善(P=0·0078)。
  • sBCMA正常化者总缓解率显著提高(P<0·0001)。
  • 所有达到完全缓解(CR)的患者均出现sBCMA正常化,且正常化时间(中位0·9个月)快于CR时间(5·0个月;P=0·0036)。

关键数值与推荐

  • sBCMA正常参考范围定义为<82·59 ng/ml。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Serum B-cell maturation antigen (sBCMA) is a novel biomarker for B-cell malignancies. A normal reference range (<82·59 ng/ml) has been recently established but the impact of achieving normal levels to outcomes for patients receiving treatment for B-cell malignancies has not been studied. We first found that among multiple myeloma (MM) patients starting a new treatment, those who begin treatment within normal sBCMA limits (<82·59 ng/ml) have improved progression-free survival (PFS; P = 0·0398) and overall survival (OS; P = 0·0217) than those who do not. Furthermore, among patients who begin treatment with elevated (≥82·59 ng/ml) sBCMA levels, we assessed the relationship of a decrease in sBCMA to the normal range to OS and found that those who normalize sBCMA demonstrated improved OS (P = 0·0078). Normalizing patients also experienced a markedly improved overall response rate (P < 0·0001). Moreover, all patients who achieved complete remission (CR) showed normalization of sBCMA, and time to normalization (median 0·9 months) was faster than time to CR (5·0 months; P = 0·0036) for these patients. These results suggest that normalization of sBCMA may be an accurate predictor of OS for MM patients during treatment and predict for a higher likelihood of response.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Jew S, Chang T, Bujarski S, et al. Normalization of serum B-cell maturation antigen levels predicts overall survival among multiple myeloma patients starting treatment. Br J Haematol. 2020. PMID: 32441777. doi:10.1111/bjh.16752

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。